David Dai
Stock Analyst at UBS
(0.42)
# 3,981
Out of 4,853 analysts
22
Total ratings
21.05%
Success rate
-28.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $17 → $2 | $1.83 | +9.29% | 2 | May 16, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $30 → $24 | $9.07 | +164.61% | 2 | May 12, 2025 | |
| NUVL Nuvalent | Upgrades: Buy | $100 | $76.79 | +30.23% | 2 | Mar 14, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $27 → $14 | $6.45 | +117.05% | 2 | Mar 6, 2025 | |
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $37.70 | -36.34% | 1 | Oct 24, 2024 | |
| BPMC Blueprint Medicines | Initiates: Neutral | $88 | $128.10 | -31.30% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $3.13 | +538.98% | 1 | Oct 24, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $35 | $12.19 | +187.24% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $57.58 | +25.04% | 1 | Oct 24, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $69 | $25.13 | +174.57% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $21.10 | +136.97% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $26.57 | +125.82% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $10.96 | +237.59% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.79 | +3,439.82% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $13.00 | +207.69% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.50 | +2,575.59% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.89 | +2,545.50% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $33.33 | +56.02% | 1 | Mar 17, 2020 |
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $1.83
Upside: +9.29%
Cullinan Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $9.07
Upside: +164.61%
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $76.79
Upside: +30.23%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27 → $14
Current: $6.45
Upside: +117.05%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $37.70
Upside: -36.34%
Blueprint Medicines
Oct 24, 2024
Initiates: Neutral
Price Target: $88
Current: $128.10
Upside: -31.30%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $3.13
Upside: +538.98%
Nurix Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $35
Current: $12.19
Upside: +187.24%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $57.58
Upside: +25.04%
Janux Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $25.13
Upside: +174.57%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $21.10
Upside: +136.97%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $26.57
Upside: +125.82%
Oct 24, 2024
Initiates: Buy
Price Target: $37
Current: $10.96
Upside: +237.59%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.79
Upside: +3,439.82%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $13.00
Upside: +207.69%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.50
Upside: +2,575.59%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $1.89
Upside: +2,545.50%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $33.33
Upside: +56.02%